Breaking News Instant updates and real-time market news.

PTGX

Protagonist Therapeutics

$7.92

-0.2 (-2.46%)

07:14
11/06/18
11/06
07:14
11/06/18
07:14

Protagonist Therapeutics reports results from Phase 1 study of PTG-200

Protagonist Therapeutics announced top-line results from the Phase 1 study of PTG-200, an oral peptide interleukin-23 receptor antagonist, in 80 normal healthy volunteers. Results of the randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study demonstrated that administration of PTG-200 was well-tolerated. No serious adverse events or dose-limiting toxicities were observed. The pharmacokinetic and pharmacodynamic parameters were consistent with the gastrointestinal-restricted design of PTG-200.

PTGX Protagonist Therapeutics
$7.92

-0.2 (-2.46%)

03/27/18
BMOC
03/27/18
NO CHANGE
Target $13
BMOC
Outperform
Protagonist Therapeutics price target lowered to $13 from $42 at BMO Capital
BMO Capital analyst M. Ian Somaiya slashed his price target on Protagonist Therapeutics (PTGX) to $13 following the announcement that the company is discontinuing its Phase 2b study of PTG-100 in patients with moderate to severe ulcerative colitis. Somaiya adds that his valuation is now driven by the risk-adjusted sales model for PTG-200, which "represents a higher probability clinical program with peak sales of over $2B". The analyst also notes that he continues to exclude the clinical data of PTG-300 from his model. Despite the steep price target revision, Somaiya keeps his Outperform rating and recommends that investors buy into the weakness after the PTG-100 clinical disappointment on anticipated PTG-200 data and the advancement of Johnson&Johnson (JNJ) - shared Stelara.
06/06/18
LEHM
06/06/18
DOWNGRADE
Target $8.5
LEHM
Equal Weight
Protagonist downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded Protagonist Therapeutics to Equal Weight and lowered his price target for the shares to $8.50 from $30. The analyst continues to see value in the company's pipeline assets, but does expect achievement of key catalysts until the second half of 2019. As such, the analyst sees greater near-term potential in small cap names with catalysts upcoming, such as Foamix (FOMX).
08/06/18
LEER
08/06/18
NO CHANGE
Target $21
LEER
Outperform
Protagonist price target raised to $21 after study re-analysis at Leerink
Leerink analyst Joseph P. Schwartz raised his price target on Protagonist Therapeutics shares to $21 from $13 after the company announced results from an independent blinded re-analysis of the Phase 2 PROPEL study of oral alpha-4-beta-7 integrin antagonist PTG-100 for the treatment of patients with ulcerative colitis. He maintains an Outperform rating on Protagonist shares.
08/06/18
LEER
08/06/18
NO CHANGE
Target $21
LEER
Outperform
Protagonist Therapeutics' PTG-100 'back on track,' says Leerink
Leerink analyst Joseph Schwartz says PTG-100 in Ulcerative colitis is "back on track," increasing his confidence in Protagonist Therapeutics' peptide technology platform. The analyst notes that the company reported this morning an unexpected, but very positive, turnaround of its lead program, PTG-100, and will now pursue late-stage clinical development, assuming a positive discussion with the FDA occurs in 2H. While it is unfortunate that the program lost some time when the data set was initially mis-scored and deemed futile when in fact today's news suggests that PTG-100 could have robust clinical efficacy, Schwartz believes that Protagonist's persistence to uncover the truth leading to the resuscitation of the program is positive. The analyst reiterates an Outperform rating on the stock and raised his price target on the shares to $21 from $13.

TODAY'S FREE FLY STORIES

NVDA

Nvidia

$202.65

5.43 (2.75%)

07:26
11/16/18
11/16
07:26
11/16/18
07:26
Recommendations
Nvidia analyst commentary  »

Nvidia likely to remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

AXP

American Express

$109.52

1.75 (1.62%)

, COF

Capital One

$89.21

0.29 (0.33%)

07:26
11/16/18
11/16
07:26
11/16/18
07:26
Recommendations
American Express, Capital One analyst commentary  »

American Express new top…

AXP

American Express

$109.52

1.75 (1.62%)

COF

Capital One

$89.21

0.29 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BCRX

BioCryst

$7.31

0.31 (4.43%)

07:26
11/16/18
11/16
07:26
11/16/18
07:26
Hot Stocks
BioCryst presents BCX7353 data at ACAAI meeting »

BioCryst presented data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

UBSH

Union Bankshares

$34.26

0.455 (1.35%)

07:25
11/16/18
11/16
07:25
11/16/18
07:25
Recommendations
Union Bankshares analyst commentary  »

Union Bankshares deserves…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$1.37

0.14 (11.38%)

07:24
11/16/18
11/16
07:24
11/16/18
07:24
Downgrade
J.C. Penney rating change  »

J.C. Penney downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

07:23
11/16/18
11/16
07:23
11/16/18
07:23
Recommendations
Nvidia analyst commentary  »

Nvidia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

TPR

Tapestry

$40.99

-0.11 (-0.27%)

07:23
11/16/18
11/16
07:23
11/16/18
07:23
Recommendations
Tapestry analyst commentary  »

Tapestry price target cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

IFF

International Flavors

$142.28

1.01 (0.71%)

07:23
11/16/18
11/16
07:23
11/16/18
07:23
Initiation
International Flavors initiated  »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOG

GasLog

$20.02

0.17 (0.86%)

, GLOP

GasLog Partners

$24.01

0.16 (0.67%)

07:22
11/16/18
11/16
07:22
11/16/18
07:22
Hot Stocks
GasLog, GasLog Partners to modify IDR »

GasLog (GLOG) and GasLog…

GLOG

GasLog

$20.02

0.17 (0.86%)

GLOP

GasLog Partners

$24.01

0.16 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KORS

Michael Kors

$47.22

-0.77 (-1.60%)

07:21
11/16/18
11/16
07:21
11/16/18
07:21
Downgrade
Michael Kors rating change  »

Michael Kors downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

07:21
11/16/18
11/16
07:21
11/16/18
07:21
Recommendations
Nvidia analyst commentary  »

Nvidia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

GAB

Gabelli Eqty Trust

$6.03

0.02 (0.33%)

07:20
11/16/18
11/16
07:20
11/16/18
07:20
Hot Stocks
Gabelli backs 10% distribution policy, raises Q4 distribution to 19c per share »

The board of The Gabelli…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$1.37

0.14 (11.38%)

07:20
11/16/18
11/16
07:20
11/16/18
07:20
Downgrade
J.C. Penney rating change  »

J.C. Penney downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
11/16/18
11/16
07:20
11/16/18
07:20
General news
FX Update: The dollar has traded mixed »

FX Update: The dollar has…

07:20
11/16/18
11/16
07:20
11/16/18
07:20
General news
Canada manufacturing preview »

Canada manufacturing…

AMAT

Applied Materials

$35.03

1.44 (4.29%)

07:19
11/16/18
11/16
07:19
11/16/18
07:19
Recommendations
Applied Materials analyst commentary  »

Citi adds Applied…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$52.33

-4.05 (-7.18%)

07:18
11/16/18
11/16
07:18
11/16/18
07:18
Recommendations
Blueprint Medicines analyst commentary  »

Blueprint Medicines data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

CUB

Cubic

$65.71

1.78 (2.78%)

07:18
11/16/18
11/16
07:18
11/16/18
07:18
Recommendations
Cubic analyst commentary  »

Cubic well positioned for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$64.59

1.09 (1.72%)

07:17
11/16/18
11/16
07:17
11/16/18
07:17
Periodicals
Citi says clients are adjusting supply chains due to trade war, CNBC reports »

Citi said their corporate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

SIGI

Selective Insurance

$64.11

1.81 (2.91%)

07:17
11/16/18
11/16
07:17
11/16/18
07:17
Initiation
Selective Insurance initiated  »

Selective Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AGIO

Agios Pharmaceuticals

$67.26

3.54 (5.56%)

07:16
11/16/18
11/16
07:16
11/16/18
07:16
Hot Stocks
Agios Pharmaceuticals presents data from AG-881 study at SNO »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

JCP

J.C. Penney

$1.37

0.14 (11.38%)

07:15
11/16/18
11/16
07:15
11/16/18
07:15
Downgrade
J.C. Penney rating change  »

J.C. Penney downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRU

Prudential

$92.49

-0.27 (-0.29%)

07:15
11/16/18
11/16
07:15
11/16/18
07:15
Recommendations
Prudential analyst commentary  »

Citi opens positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

07:14
11/16/18
11/16
07:14
11/16/18
07:14
Recommendations
Williams-Sonoma analyst commentary  »

Williams-Sonoma has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

07:14
11/16/18
11/16
07:14
11/16/18
07:14
Recommendations
Nvidia analyst commentary  »

Nvidia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.